Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

News Releases 2018

The information set forth in each press release posted on this page was factually accurate on the date it was issued. While these press releases remain on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of the press releases should not rely upon the information as current or accurate after their issuance dates.

Keyword Search
Search by Year
06/04/18Charles River Laboratories to Present at Jefferies and William Blair ConferencesPrinter Friendly Version
05/10/18Charles River Laboratories Announces First-Quarter 2018 Results from Continuing OperationsPrinter Friendly Version
05/03/18Charles River Laboratories Announces Extended Relationship with The Michael J. Fox FoundationPrinter Friendly Version
05/01/18Charles River Laboratories Expands Services for Early Discovery ScreeningPrinter Friendly Version
04/12/18Charles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference CallPrinter Friendly Version
04/10/18Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018Printer Friendly Version
04/09/18Charles River Laboratories and PathoQuest Expand Strategic Biologics PartnershipPrinter Friendly Version
04/03/18Charles River Laboratories Announces Closing of Senior Notes OfferingPrinter Friendly Version
04/03/18Charles River Laboratories Completes the Acquisition of MPI ResearchPrinter Friendly Version
03/26/18Charles River Laboratories Announces Refinancing of Credit Facilities and Offering of $500 Million of Senior NotesPrinter Friendly Version
03/08/18Charles River Laboratories Makes Expansions to Global Biologics InfrastructurePrinter Friendly Version
03/05/18Charles River Laboratories to Present at Raymond James and Barclays ConferencesPrinter Friendly Version
02/21/18Charles River Laboratories Announces New Tumor Model CompendiumPrinter Friendly Version
02/13/18Charles River Laboratories Announces Executive Management AppointmentsPrinter Friendly Version
02/13/18Charles River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 GuidancePrinter Friendly Version
02/13/18Charles River Laboratories to Acquire MPI ResearchPrinter Friendly Version
02/01/18Charles River Laboratories Makes Investments in High-Throughput Screening InfrastructurePrinter Friendly Version
01/25/18Charles River Laboratories Schedules Fourth-Quarter 2017 Earnings and 2018 Guidance Release and Conference CallPrinter Friendly Version
01/16/18Charles River Laboratories Adds Jean-Paul Mangeolle to Board of DirectorsPrinter Friendly Version
01/11/18Charles River Laboratories Acquires KWS BioTestPrinter Friendly Version
01/08/18Charles River Laboratories to Present at J.P. Morgan Healthcare ConferencePrinter Friendly Version

Stock Quote

CRL (common)
Change (%)
+ 0.48 (0.41%)
Data as of 06/22/18 4:03 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.

Refresh Quote

Investor Hotline

877-567-6CRL (6275)